Literature DB >> 1341604

The therapeutic use of albumin.

G E Hastings1, P G Wolf.   

Abstract

In this review, we condense and summarize the results of studies on the therapeutic use of human albumin to promote the more efficient use of this costly resource. Reports of major controlled and uncontrolled therapeutic trials, reviews, and summary articles published in English between 1972 and 1991 were identified through library and MEDLINE searches. Case series, prospective studies, and blinded therapeutic trials were identified from the bibliographies of these sources. All sources were critically evaluated for information about the comparative physiologic results and patient outcomes of the therapeutic use of albumin solutions, crystalloid solutions, and volume expanders other than albumin. The therapeutic use of albumin is of marginal benefit for many conditions for which it has been administered, apparently because of the body's capacity to quickly compensate for rapid colloid osmotic shifts. Human studies show little or no demonstrable value for albumin when it is administered for nutritional supplementation, wound healing, perioperative fluid replacement, treatment of early thermal injury, or therapy during extensive retroperitoneal surgery (including aortic aneurysm resection). Therapeutic albumin has well-defined value in several special circumstances: large-volume paracentesis in cirrhotic patients, acute nephrotic syndromes with diuretic resistance, organ transplantation, and plasmapheresis. Additional studies are needed to compare the efficacy of albumin with other volume expanders. For most purposes, balanced crystalloid solutions are satisfactory substitutes for colloid volume expanders and can be obtained at a fraction of the cost of colloid volume expanders.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341604     DOI: 10.1001/archfami.1.2.281

Source DB:  PubMed          Journal:  Arch Fam Med        ISSN: 1063-3987


  10 in total

1.  Guidelines for the clinical use of albumin: comparison of use in two Italian hospitals and a third hospital without guidelines.

Authors:  Antonietta Martelli; Paolo Strada; Ildefonso Cagliani; Giovanni Brambilla
Journal:  Curr Ther Res Clin Exp       Date:  2003-11

Review 2.  The advances and perspectives of recombinant protein production in the silk gland of silkworm Bombyx mori.

Authors:  Hanfu Xu
Journal:  Transgenic Res       Date:  2014-08-12       Impact factor: 2.788

3.  Large-scale production of functional human serum albumin from transgenic rice seeds.

Authors:  Yang He; Tingting Ning; Tingting Xie; Qingchuan Qiu; Liping Zhang; Yunfang Sun; Daiming Jiang; Kai Fu; Fei Yin; Wenjing Zhang; Lang Shen; Hui Wang; Jianjun Li; Qishan Lin; Yunxia Sun; Hongzhen Li; Yingguo Zhu; Daichang Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

4.  Autologous albumin enhances the humoral immune response to capsular polysaccharide covalently coattached to bacteria-sized latex beads.

Authors:  Jesus Colino; Leah Duke; Clifford M Snapper
Journal:  Eur J Immunol       Date:  2014-02-27       Impact factor: 5.532

5.  Crystal structures of serum albumins from domesticated ruminants and their complexes with 3,5-diiodosalicylic acid.

Authors:  Anna Bujacz; Julita A Talaj; Kamil Zielinski; Agnieszka J Pietrzyk-Brzezinska; Piotr Neumann
Journal:  Acta Crystallogr D Struct Biol       Date:  2017-10-25       Impact factor: 7.652

6.  Expression and purification of recombinant human serum albumin from selectively terminable transgenic rice.

Authors:  Qing Zhang; Hui Yu; Feng-zhen Zhang; Zhi-cheng Shen
Journal:  J Zhejiang Univ Sci B       Date:  2013-10       Impact factor: 3.066

7.  Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window.

Authors:  Tiffany N Eady; Larissa Khoutorova; Kristal D Atkins; Nicolas G Bazan; Ludmila Belayev
Journal:  Exp Transl Stroke Med       Date:  2012-09-14

8.  Immunotoxicity assessment of rice-derived recombinant human serum albumin using human peripheral blood mononuclear cells.

Authors:  Kai Fu; Qin Cheng; Zhenwei Liu; Zhen Chen; Yan Wang; Honggang Ruan; Lu Zhou; Jie Xiong; Ruijing Xiao; Shengwu Liu; Qiuping Zhang; Daichang Yang
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

9.  Production of Human Albumin in Pigs Through CRISPR/Cas9-Mediated Knockin of Human cDNA into Swine Albumin Locus in the Zygotes.

Authors:  Jin Peng; Yong Wang; Junyi Jiang; Xiaoyang Zhou; Lei Song; Lulu Wang; Chen Ding; Jun Qin; Liping Liu; Weihua Wang; Jianqiao Liu; Xingxu Huang; Hong Wei; Pumin Zhang
Journal:  Sci Rep       Date:  2015-11-12       Impact factor: 4.379

Review 10.  Distinct Immunologic Properties of Soluble Versus Particulate Antigens.

Authors:  Clifford M Snapper
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.